A selective alpha 2-adrenergic antagonist,
midaglizole, has been recently reported to have efficacy in patients with
asthma. To understand the mechanisms, we investigated the effect of
midaglizole on the cyclic 3', 5'-adenosine monophosphate (cAMP) production in human mononuclear cells (MNCs). MNCs were separated by a
histopaque gradient from 10 normal subjects and 10 subjects with
asthma. cAMP was measured by RIA kits.
Midaglizole (10 mumol/L) significantly enhanced
isoproterenol-induced cAMP production in both groups, although
midaglizole (from 1 to 100 mumol/L) did not increase the cAMP production by itself. The percent increase in cAMP was more in subjects with
asthma (183.8%) than in normal subjects (140.4%); however, the absolute increase was not different.
Platelet-activating factor has been demonstrated to inhibit beta-agonist-induced cAMP production in several mammalian tissues, including human MNCs.
Midaglizole also prevented
platelet-activating factor-induced desensitization of the cAMP response to
isoproterenol in MNCs. These findings suggest that
midaglizole may be a useful additional agent for the
therapy of
bronchial asthma through an enhancement of the cAMP production.